…
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Allarity Therapeutics is a clinical-stage biotech developing oncology therapies and predictive biomarker tools to inform treatment selection. Long-term growth may be driven by positive clinical trial results, regulatory approvals and wider adoption of precision oncology, which could support partnering and commercialization.
Key risks are clinical trial failure, regulatory setbacks, limited liquidity and funding needs, and stiff competition in oncology; investors should monitor cash runway and trial readouts.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -11.23M | -24.90M | -11.82M | -17.58M | -26.52M |
| Minority interest | - | - | - | - | 0.00M |
| Net income | -11.23M | -24.52M | -11.90M | -16.06M | -26.65M |
| Selling general administrative | 6.32M | 11.44M | 10.03M | 9.96M | 12.36M |
| Gross profit | 0.32M | -0.01M | -0.04M | - | - |
| Reconciled depreciation | -0.01M | 0.01M | 0.03M | 0.06M | 0.11M |
| Ebit | -11.03M | -24.24M | -11.32M | -34.46M | -26.56M |
| Ebitda | -11.05M | -24.23M | -11.28M | -16.80M | -28.27M |
| Depreciation and amortization | -0.01M | 0.01M | 0.04M | 17.66M | -1.72M |
| Non operating income net other | - | - | - | 16.88M | - |
| Operating income | -12.61M | -27.24M | -17.13M | -34.46M | -26.56M |
| Other operating expenses | 12.93M | 27.24M | 17.13M | 16.89M | 26.56M |
| Interest expense | 0.18M | 0.65M | 0.50M | 0.22M | 0.50M |
| Tax provision | 0.00M | -0.38M | -0.30M | -1.52M | 0.13M |
| Interest income | 0.80M | 0.53M | 0.03M | 0.03M | - |
| Net interest income | 0.62M | -0.12M | -0.35M | -0.19M | -1.85M |
| Non recurring | - | - | - | 17.57M | - |
| Income tax expense | - | -0.38M | 0.08M | -1.52M | 0.13M |
| Total revenue | 0.32M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 12.93M | 27.24M | 17.13M | 16.89M | 26.56M |
| Cost of revenue | - | 0.01M | 0.04M | - | - |
| Total other income expense net | 1.37M | 2.35M | 5.31M | 16.88M | 0.04M |
| Net income from continuing ops | -11.23M | -24.52M | -13.02M | -16.06M | -26.65M |
| Net income applicable to common shares | - | - | - | -21.05M | -26.65M |
| Preferred stock and other adjustments | - | - | - | 4.99M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 18.26M | 22.65M | 11.86M | 14.54M | 49.63M |
| Intangible assets | - | - | 9.87M | 9.55M | 28.14M |
| Other current assets | 2.35M | 0.58M | 0.86M | 2.07M | 1.50M |
| Total liab | 8.43M | 10.84M | 14.61M | 12.65M | 30.85M |
| Total stockholder equity | 9.83M | 11.81M | -2.75M | 1.89M | 18.78M |
| Deferred long term liab | - | - | - | 1.43M | - |
| Other current liab | 2.67M | 5.23M | 4.39M | 2.32M | 11.27M |
| Common stock | 0.00M | 0.00M | - | 0.00M | 0.81M |
| Capital stock | 0.00M | 0.00M | 1.74M | 2.00M | 1.44M |
| Retained earnings | -130.20M | -118.97M | -94.45M | -82.55M | -66.49M |
| Other liab | - | - | - | 0.35M | 9.14M |
| Cash | 14.69M | 19.53M | 0.17M | 2.03M | 19.55M |
| Total current liabilities | 8.43M | 10.84M | 14.17M | 11.22M | 20.72M |
| Current deferred revenue | - | - | 0.06M | - | 8.65M |
| Net debt | -13.29M | -18.18M | 1.13M | 1.71M | -18.47M |
| Short term debt | 1.40M | 1.35M | 1.30M | 2.65M | 0.10M |
| Short long term debt | 1.40M | 1.35M | 1.30M | 2.64M | - |
| Short long term debt total | 1.40M | 1.35M | 1.30M | 3.73M | 1.09M |
| Other stockholder equity | 141.04M | 131.13M | 90.37M | 83.16M | 84.43M |
| Property plant equipment | - | - | - | 0.02M | 0.09M |
| Total current assets | 17.93M | 22.34M | 1.97M | 4.97M | 21.05M |
| Long term investments | - | - | - | - | 0.35M |
| Net tangible assets | - | - | - | -7.66M | -9.98M |
| Short term investments | - | 0.07M | - | 0.00M | - |
| Net receivables | 0.90M | 2.23M | 0.95M | 0.87M | 1.34M |
| Long term debt | - | - | - | 1.08M | 0.98M |
| Inventory | - | - | - | - | -1.34M |
| Accounts payable | 4.28M | 4.18M | 8.42M | 6.25M | 0.70M |
| Accumulated other comprehensive income | -1.02M | -0.35M | -0.41M | -0.72M | -0.60M |
| Common stock total equity | - | - | - | 0.00M | - |
| Retained earnings total equity | - | - | - | -82.55M | - |
| Non currrent assets other | - | - | - | 0.01M | 0.35M |
| Non current assets total | 0.33M | 0.31M | 9.89M | 9.58M | 28.58M |
| Capital lease obligations | - | - | 0.00M | 0.01M | 0.11M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.30M | -0.02M | 0.79M | 1.00M |
| Change to liabilities | - | - | - | 1.37M | -1.31M |
| Total cashflows from investing activities | -0.01M | -0.30M | - | 0.79M | 1.00M |
| Net borrowings | 0.00M | 0.00M | -2.65M | 1.00M | 0.97M |
| Total cash from financing activities | 10.65M | 36.79M | 10.99M | -1.31M | 33.82M |
| Change to operating activities | - | - | - | -6.52M | 6.87M |
| Net income | -11.23M | -24.52M | -11.90M | -16.06M | -26.65M |
| Change in cash | -4.85M | 19.37M | -1.86M | -17.53M | 19.26M |
| Begin period cash flow | 19.53M | 0.17M | 2.03M | 19.55M | 0.30M |
| End period cash flow | 14.69M | 19.53M | 0.17M | 2.03M | 19.55M |
| Total cash from operating activities | -14.82M | -17.35M | -12.74M | -16.82M | -15.05M |
| Issuance of capital stock | 13.84M | 40.29M | 18.05M | 0.00M | 32.12M |
| Depreciation | -0.01M | 0.01M | 0.04M | 0.06M | 0.11M |
| Other cashflows from investing activities | -0.01M | -0.30M | - | 0.81M | - |
| Dividends paid | - | - | 10.99M | 1.51M | - |
| Change to account receivables | -0.10M | 0.04M | -0.03M | - | 0.00M |
| Sale purchase of stock | -3.19M | -3.50M | -6.65M | -1.51M | - |
| Other cashflows from financing activities | 10.65M | -0.56M | -3.25M | 0.20M | 4.64M |
| Change to netincome | - | - | - | 16.52M | 5.92M |
| Capital expenditures | 0.01M | 0.30M | 0.00M | 0.02M | 0.02M |
| Cash flows other operating | - | - | - | -18.70M | - |
| Cash and cash equivalents changes | - | - | - | -17.34M | - |
| Change in working capital | -5.68M | 0.06M | 3.35M | -0.33M | 5.57M |
| Stock based compensation | 0.48M | 0.07M | -0.07M | 1.75M | 6.37M |
| Other non cash items | -9.14M | 7.47M | -4.26M | -0.63M | -0.47M |
| Free cash flow | -14.83M | -17.65M | -12.74M | -16.84M | -15.05M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALLR Allarity Therapeutics Inc |
0.00 0.09% |
0.88 | - | - | 61.79 | 2.03 | 20.77 | -0.08 |
| NVO Novo Nordisk A/S |
-1.21 2.90% |
40.40 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.15 1.14% |
531.64 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.70 0.49% |
957.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. James G. Cullem J.D. | Interim CEO, Chief Bus. Officer, Sr. VP of Corp. Devel. & Director | 1969 |
| Dr. Marie Foegh DrSc, M.D. | Chief Medical Officer | 1944 |
| Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D. | Co-Founder | 1955 |
| Dr. Steen Meier Knudsen Ph.D. | Founder & Chief Scientific Officer | 1961 |
| Mr. Thomas H. Jensen | Founder, Sr. VP of Investor Relations & Director | 1978 |
| Mr. Claus Frisenberg Pedersen | Chief Commercial Officer | 1972 |
| Ms. Joan Brown | Interim CFO & Director of Financial Reporting | 1953 |
| Ms. Annie Rasmussen | Chief of Clinical Operations | 1957 |
| Mr. Thomas H. Jensen | Founder, CEO, Senior VP of Investor Relations & Director | 1978 |
| Ms. Joan Y. Brown | Interim CFO | 1954 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.